Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

@article{Herben1999PhaseIA,
  title={Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.},
  author={Virginie M.M. Herben and R van Gijn and Jan H. M. Schellens and Margaret E. Schot and Jan Lieverst and Michel J. X. Hillebrand and Nadja E. Schoemaker and M G Porro and Jos H. Beijnen and Wim W ten Bokkel Huinink},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 6},
  pages={1906-14}
}
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of 9-aminocamptothecin (9-AC) in a colloidal dispersion (CD) formulation administered as a 30-minute intravenous (IV) infusion over 5 consecutive days every 3 weeks. PATIENTS AND METHODS Patients with solid tumors refractory to standard therapy were entered onto the study. The starting dose was 0.4 mg/m(2)/d. The MTD was assessed on the first cycle and was defined as the dose at which… CONTINUE READING